Dirks-Naylor, A
In the LEADER trial, over 9,340 patients with type 2 diabetes and high cardiovascular disease risk underwent randomization to liraglutide or placebo and were followed for a median of 3.8 years resulting in a 13% risk reduction in a combined endpoint of death from cardiovascular cause, nonfatal myocardial infarction, or nonfatal stroke [46]
La Administracin de Alimentos y Medicamentos de Estados Unidos aprob el lunes la primera pldora GLP-1 para la obesidad, desarrollada por Novo Nordisk, fabricante de Wegovy
According to our latest, AlphaWise survey, 17 percent of U.S
Chen L, Hambright WS, Na R, Ran Q
With Vitamin C: Glutathione are often combined with Vitamin C to boost antioxidant activity, enhance skin brightening, and improve absorption